US EditionPublished • loading... • Updated
Novo Nordisk fights to keep Medicaid paying for weight-loss drugs - Regional Media News
Summary by regionalmedianews.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Novo Nordisk fights to keep Medicaid paying for weight-loss drugs - Regional Media News
By Dan Levine and Chad Terhune (Reuters) -Novo Nordisk, which lobbied to win Medicaid reimbursement for its obesity drug Wegovy, is fighting to keep that coverage as some U.S. states struggle with the treatment’s costs, according to state documents, company emails and interviews with lawmakers and advocates. Novo’s lobbying efforts helped to convince 14 U.S. states to cover Wegovy for low-income patients under their Medicaid health insurance pro…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
